Macroflux Corp.
This article was originally published in Start Up
Executive Summary
These days, many start-ups aim to improve upon existing drugs, and swipe some of their market share, by dint of novel delivery methods. Macroflux has those aspirations, and considerably more means to realize them than most firms founded just six months ago. The company is a spin-out from J&J's Alza Corp., one of the most productive drug delivery outfits ever. Macroflux will commercialize a patch-based drug delivery system that the company expects will be a virtually painless way to deliver therapeutic proteins, peptides, and vaccines.